失代偿乙型肝炎肝硬化患者应用阿德福韦酯与拉米夫定的疗效观察

Efficacy of loss of decompensated liver cirrhosis in patients with adefovir dipivoxil and lamivudine

目的：观察应用阿德福韦酯、拉米夫定单药或联合治疗失代偿乙型肝炎肝硬化患者的疗效.方法：将102例失代偿乙型肝炎肝硬化患者随机分为3组,所有患者都给予常规治疗,另外分别予拉米夫定100mg/d（LAM组）,阿德福韦酯10mg/d（ADV组）,拉米夫定100mg/d＋阿德福韦酯10mg/d（联合组）,疗程均为72周.结果：治疗72周,3组患者ALT、白蛋白、总胆红素均有明显好转,治疗前后比较有统计学意义（P〈0.05）.结论：阿德福韦酯拉米夫定联合或单药治疗能有效改善失代偿乙型肝炎肝硬化患者肝功能,联合治疗更有效快速地抑制乙肝病毒的复制,并且病毒变异概率小.

Objective：To observe the application of adefovir dipivoxil, lamivudine or combined treatment efficacy in patients with decompensated cirrhosis of hepatitis b. Methods：102 cases of patients with decompensated cirrhosis of hepatitis b were randomly divided into three groups： lamivudi- ne 100mg/d （LAM group） ,adefovir dipivoxil 10mg/d （ADV group） ,lamivudine 100mg/d combine adefovir dipivoxil 10mg/d （joint group） ,all were given conventional treatment, courses for 72 weeks. Result：After treatment of 72 weeks, ALT, albumin, total bilirub in three groups patients were sig- nificant improvement,with before and after treatment（P^0.05）. Conclusion between the groups after treatment,the difference were not statistically significant （P^0.05）. Conclusion：Adefovir dipivoxil combine lamivudine or single--drug treatment is effective in improving liver function in patients with decornpensated cirrhosis of hepatitis b. Combined treatment inhibits replication of the hepatitis b virus more quickly and effectively,and virus mutation probability is small.